Delivery Order SPE2DB22D3016-SPE2DB25FBAF8
Award Date
6/24/25
Potential Completion Date
6/25/25
Potential Value
$5.5K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $1,263.72 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of May 22, 2025. This contract is not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $153,284 for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 4, 2023. The contract is a firm fixed-price arrangement, and there is no set-aside designation indicated. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $110,730.45 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has a final completion date of September 9, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. This IDC...
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
The U.S. Defense Logistics Agency (DLA) has awarded a Delivery Order contract worth $2,365.92 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This Delivery Order is issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC enables DLA to efficiently procure essential...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $44,952.48 firm fixed-price delivery order contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of May 22, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a ceiling value of $75,784.30 and is a firm fixed-price delivery order with a performance period ending on May 29, 2025. The contract is not set aside and was awarded on May 28, 2025. Amerisourcebergen Drug...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,106.20 contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a period of performance through May 30, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX,...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,154.56 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is in effect through December 2025. The...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract, valued at $1,263.72, is a Firm Fixed Price Delivery Order issued by the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of June 13, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is the prime contractor for this award and...